Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | {{#lst: | + | {{#lst:Editorial board transclusions|heme}} |
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | '''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Line 15: | Line 15: | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:be34d7|Variant=1}}=== | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | ||
− | |style="background-color:#ffffbe"|Pilot, | + | |Not reported |
+ | |style="background-color:#ffffbe"|Pilot, fewer than 20 pts | ||
|- | |- | ||
|} | |} | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Plerixafor (Mozobil)]] | + | *[[Plerixafor (Mozobil)]] 0.01 to 0.02 mg/kg SC twice per day |
+ | '''Various durations''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30625055 PubMed] | + | # '''Case series:''' McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/30625055/ PubMed] |
[[Category:WHIM syndrome regimens]] | [[Category:WHIM syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Cytopenias]] | [[Category:Cytopenias]] |
Latest revision as of 20:32, 15 July 2024
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
McDermott et al. 2019 | Not reported | Pilot, fewer than 20 pts |
References
- Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed